Abstract TH270: Primary Aldosteronism Screening in Primary Care: Opportunities and Pitfalls in Interpretation
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.th270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Jill Teitelbaum und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
The 2025 AHA/ACC High Blood Pressure (BP) Guideline expanded recommended screening for Primary Aldosteronism (PA). Screening rates are low, and little is known about accuracy of interpretation and management in primary care settings. Hypothesis: PA is under-screened and underdiagnosed in primary care settings, and opportunities to intervene may be missed.
Methods
Data for patients seen in the last year with an average BP >140/90 mmHg in a single-site urban academic medical clinic were extracted from the EHR. Among patients with Aldosterone: Renin Ratio (ARR)>20 not on mineralocorticoid receptor antagonist (MRA) therapy, charts were reviewed for assay interpretation, specialist referral, plan for targeted therapy, or adrenalectomy. Providers who had not acted on results were outreached with guidance.
Results
A total of 2,917 patients were eligible for PA screening based on diagnosis of Stage II HTN (mean BP >140/90mmg), and of those, 15% (435) had been screened. A total of 74 patients had ARR >20, and 58 were not on MRA and included in review. Of 57 living patients, ratios were interpreted by providers as: 31 positive, 12 negative, and 14 without comment. Twenty patients were placed on MRA, 6 considered, and 3 deferred, and 10 eventually discontinued. Guidance was sent for 54 patients with a 1-week response rate of 57%. Common responses included scheduling an appointment, adding to problem list, and logic for deferment.
Conclusion
Although screening rates for PA were higher than in other studies, there may be misinterpretation of ARR screening, and potential opportunities for targeted therapy. Among 57 patients with ARR >20, there were 37 potential opportunities for targeted medical therapy or more work-up, representing an opportunity to improve care. Further, 85% of eligible patients were unscreened. Increased PA screening may improve overall HTN management in primary care settings; however, providers may need additional education and support. This study is limited by being single center but is strengthened by the ability to query by average BP and medication data. Further, only active medications rather than those at the time of ARR assay were known. Although ARR screening is imperfect, this analysis shows variability in interpretation and management among providers. Nonetheless, the initial response rate of >50% is encouraging. This study highlights multiple opportunities for improved BP management and provider education to manage underdiagnosed and undertreated PA.
Zitieren
APA
Teitelbaum, J., Bryant, K., & Halket, D. (2026). Abstract TH270: Primary Aldosteronism Screening in Primary Care: Opportunities and Pitfalls in Interpretation. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.th270
Vancouver
Teitelbaum J, Bryant K, Halket D. Abstract TH270: Primary Aldosteronism Screening in Primary Care: Opportunities and Pitfalls in Interpretation. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.th270
BibTeX
@article{Teitelbaum2026,
author = {Teitelbaum, Jill and Bryant, Kelsey and Halket, Douglas},
title = {Abstract TH270: Primary Aldosteronism Screening in Primary Care: Opportunities and Pitfalls in Interpretation},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.th270}
}
EUVIMED